Recruiting PHASE1 INTERVENTIONAL 2-arm NCT04999943

Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome (eDC-MDS)

A Randomized, Open-label, Clinical Trial to Compare the Safety and Efficacy of Hypomemylating Agents Monotherapy and Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome

Sponsor: Affiliated Hospital to Academy of Military Medical Sciences

Conditions Dendritic Cell Hypomethylating Agents Immunotherapy Myelodysplastic Syndromes

Interventions DC vaccine

Updated 3 times since 2021 Last updated: Aug 10, 2021 Started: Jul 1, 2021 Primary completion: Jul 1, 2026 Completion: Jul 1, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04999943, this PHASE1 trial focuses on Dendritic Cell and Hypomethylating Agents and remains actively recruiting participants. Sponsored by Affiliated Hospital to Academy of Military Medical Sciences, it has been updated 3 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Sep 2021 — Jul 2024 [monthly]

Recruiting PHASE1

First recorded

Jul 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Affiliated Hospital to Academy of Military Medical Sciences

Data source: Affiliated Hospital to Academy of Military Medical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China